Placebo + Active Comparator #1 + Active Comparator #2 + Active Comparator #3 + Lorcaserin Dose #1 + Lorcaserin Dose #2 + Lorcaserin Dose #3
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Drug Abuse
Conditions
Drug Abuse, Healthy
Trial Timeline
Dec 1, 2008 → Apr 1, 2009
NCT ID
NCT00828659About Placebo + Active Comparator #1 + Active Comparator #2 + Active Comparator #3 + Lorcaserin Dose #1 + Lorcaserin Dose #2 + Lorcaserin Dose #3
Placebo + Active Comparator #1 + Active Comparator #2 + Active Comparator #3 + Lorcaserin Dose #1 + Lorcaserin Dose #2 + Lorcaserin Dose #3 is a phase 1 stage product being developed by Eisai for Drug Abuse. The current trial status is completed. This product is registered under clinical trial identifier NCT00828659. Target conditions include Drug Abuse, Healthy.
What happened to similar drugs?
8 of 15 similar drugs in Drug Abuse were approved
Approved (8) Terminated (3) Active (5)
✅Polyene phosphatidylcholine injection 930 mg QD + Magnesium Isoglycyrrhizinate injection 200 mg QDHaisco Pharmaceutical GroupApproved
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00828659 | Phase 1 | Completed |
Competing Products
20 competing products in Drug Abuse